Roth Capital Predicts Zimmer Biomet’s Q1 Earnings (NYSE:ZBH)

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Equities research analysts at Roth Capital issued their Q1 2025 earnings estimates for Zimmer Biomet in a report issued on Friday, February 7th. Roth Capital analyst J. Wittes anticipates that the medical equipment provider will post earnings of $1.75 per share for the quarter. The consensus estimate for Zimmer Biomet’s current full-year earnings is $8.25 per share. Roth Capital also issued estimates for Zimmer Biomet’s Q2 2025 earnings at $2.04 EPS, Q3 2025 earnings at $2.01 EPS, Q4 2025 earnings at $2.41 EPS, FY2025 earnings at $8.20 EPS and FY2026 earnings at $8.89 EPS.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period last year, the business posted $2.20 earnings per share.

Other analysts have also issued research reports about the stock. Raymond James decreased their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and raised their price target for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. JMP Securities reissued a “market outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet in a report on Friday, February 7th. Finally, Royal Bank of Canada dropped their target price on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, Zimmer Biomet has a consensus rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Trading Down 1.3 %

NYSE ZBH opened at $99.13 on Monday. Zimmer Biomet has a 52 week low of $98.94 and a 52 week high of $133.90. The business has a 50 day moving average price of $107.14 and a 200-day moving average price of $107.99. The company has a quick ratio of 0.70, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The company has a market cap of $19.73 billion, a price-to-earnings ratio of 22.28, a P/E/G ratio of 1.83 and a beta of 1.02.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were issued a $0.24 dividend. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.97%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Hedge Funds Weigh In On Zimmer Biomet

Several institutional investors and hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC lifted its position in shares of Zimmer Biomet by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock valued at $524,942,000 after buying an additional 125,852 shares during the last quarter. Van ECK Associates Corp raised its stake in Zimmer Biomet by 5.9% in the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider’s stock valued at $417,814,000 after acquiring an additional 218,688 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in Zimmer Biomet by 0.4% during the third quarter. Allspring Global Investments Holdings LLC now owns 2,569,311 shares of the medical equipment provider’s stock valued at $277,357,000 after purchasing an additional 9,990 shares during the last quarter. Hotchkis & Wiley Capital Management LLC boosted its position in Zimmer Biomet by 49.1% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock worth $189,161,000 after purchasing an additional 577,320 shares during the period. Finally, Equity Investment Corp increased its stake in shares of Zimmer Biomet by 57.2% in the fourth quarter. Equity Investment Corp now owns 1,021,062 shares of the medical equipment provider’s stock worth $107,855,000 after purchasing an additional 371,653 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.